GlassScriptPhysician profile
Leili Parsa
NPI 1710111794
$3,535.16
in general payments reported to CMS, 2019-2025
27 companies · $1,854 in 2025
The $1,854 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $217 · 2021: $170 · 2022: $114 · 2023: $372 · 2024: $548 · 2025: $1,854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,760 · Education: $13.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,760.32 |
| Education | $13.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $723.06 | 2019-2025 | |
| Abbvie INC. | $690.36 | 2019-2025 | |
| Amgen INC. | $418.56 | 2019-2025 | Uplizna, Evenity, Krystexxa |
| Ucb, INC. | $272.10 | 2021-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $156.78 | 2023-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $144.69 | 2023-2025 | Orencia |
| Janssen Biotech, INC. | $132.95 | 2019-2025 | Tremfya |
| Ani Pharmaceuticals, INC. | $126.58 | 2025 | Purified Cortrophin Gel, Sovuna |
| Radius Health, INC. | $124.56 | 2024-2025 | Tymlos |
| Pfizer INC. | $117.47 | 2024-2025 | |
| Cardinal Health 110 LLC | $100.00 | 2021 | |
| Glaxosmithkline, LLC. | $57.13 | 2023-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $47.12 | 2024-2025 | Saphnelo |
| Genzyme Corporation | $45.61 | 2025 | |
| Sobi, INC | $44.45 | 2024-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $42.26 | 2025 | Hymovis, Triluron |
| Alexion Pharmaceuticals, INC. | $39.73 | 2025 | Strensiq |
| Fresenius Kabi USA, LLC | $34.67 | 2025 | |
| Sandoz INC. | $31.44 | 2025 | Hyrimoz |
| Horizon Therapeutics Plc | $29.87 | 2022 | |
| US Oncology Corporate, INC. | $26.51 | 2025 | |
| Genentech USA, INC. | $25.12 | 2025 | Actemra |
| Organon LLC | $24.72 | 2024 | |
| Mallinckrodt Hospital Products INC. | $22.34 | 2025 | Acthar |
| Lilly USA, LLC | $20.14 | 2023 | Taltz |
| Invivyd INC | $18.76 | 2025 | Pemgarda |
| Tonix Medicines, INC. | $18.18 | 2025 | Tonmya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leili Parsa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.